Tarsus Q2 net loss $5.7M; TP-03 NDA submission for Demodex blepharitis on track

Tarsus Pharmaceuticals, Inc.

2022-Q2 EPS reported -$1.15 revenue$15,816,000

Net loss of $5.7M vs net income of $6.3M in Q2 2021; revenue $15.3M from LianBio partnership.
Cash and equivalents $245.4M as of June 30, 2022; runway into at least 2026.
TP-03 met all endpoints in Saturn-2 Phase 3; NDA submission expected in H2 2022.
Initiated Ersa Phase 2a trial of TP-03 for Meibomian Gland Disease.
Expecting Phase 1b data for TP-05 Lyme disease prevention in H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.